I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Biologia Molecolare e Biotecnologie
Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246
ORIGINAL ARTICLES MICROARRAY MEETING 2003: III CONVEGNO ITALIANO SULLA TECNOLOGIA
Segrate (MI), 9-10 Giugno 2003
Minerva Biotecnologica 2003 December;15(4):235-44
Application of a cDNA microarray for the analysis of muscular dystrophies and childhood leukemias
Campanaro S. 1, De Pittà C. 1, Celegato B. 1, Millino C. 1, Romualdi C. 1, Pacchioni B. 1, Trevisan S. 1, Bellin M. 1, Cagnin S. 1, Tombolan L. 1, Fanin M. 2, Pegoraro E. 2, TE Kronnie G. 3, Pescatori M. 4, Valle G. 1, Basso G. 3, Ricci E. 4, Angelini C. 2, Lanfranchi G. 1
1 CRIBI Biotechnology Center and Departement of Biology, University of Padua, Padua, Italy;
2 Department of Neurosciences, University of Padua, Padua, Italy;
3 Department of Pediatrics, University of Padua, Padua, Italy;
4 Institute of Neurology, Catholic University, Rome, Italy and UILDM-Centre for Neuromuscular Diseases, Rome, Italy
Aim. Microarray technique can measure the expression of thousands of genes simultaneously and can identify subtle changes in expression between different biological states.
Methods. Using our cDNA collection obtained from systematic sequencing of cDNA libraries from skeletal muscle, heart and bone marrow tissues, we have developed a microarray composed of 4 670 sequences corresponding to the 400-500 bp region located at the 3’-end of cDNA transcripts.
Results. We used this microarray platform in order to investigate the expression profile in 4 different pathologies: limb girdle muscular dystrophy type 2B (LGMD 2B), facioscapulohumeral muscular dystrophy (FSHD1A), congenital muscular dystrophy (CMD) and a group of childhood leukaemias. Our aim is to compare different pathologies in order to identify significant genes whose expression characterize each single disease.
Conclusion. The cDNA microarray platform developed in our laboratory allow the identification of differentially expressed genes in muscular dystrophies and in childhood leukaemias in order to better define the molecular mechanism of these pathologies. Moreover our microarray experiments identify different forms of the same pathology on the base of the transcriptional profile.